436 related articles for article (PubMed ID: 18568776)
21. Prognostic impact of CD133 mRNA expression in 48 glioblastoma patients treated with concomitant radiochemotherapy: a prospective patient cohort at a single institution.
Metellus P; Nanni-Metellus I; Delfino C; Colin C; Tchogandjian A; Coulibaly B; Fina F; Loundou A; Barrie M; Chinot O; Ouafik L; Figarella-Branger D
Ann Surg Oncol; 2011 Oct; 18(10):2937-45. PubMed ID: 21479688
[TBL] [Abstract][Full Text] [Related]
22. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma.
Liu G; Yuan X; Zeng Z; Tunici P; Ng H; Abdulkadir IR; Lu L; Irvin D; Black KL; Yu JS
Mol Cancer; 2006 Dec; 5():67. PubMed ID: 17140455
[TBL] [Abstract][Full Text] [Related]
23. [Isolation and characterization of brain tumor stem cells in human medulloblastoma].
Li MC; Deng YW; Wu J; Chen FH; Liu JF; Fang JS
Ai Zheng; 2006 Feb; 25(2):241-6. PubMed ID: 16480595
[TBL] [Abstract][Full Text] [Related]
24. CD133 expression is associated with small round blue cell tumour morphology in human central nervous system neoplasms.
Schittenhelm J; Simon P; Harter PN; Zachskorn C; Schlaszus H; Röttger F; Winkels M; Weller M; Meyermann R; Mittelbronn M
Histopathology; 2011 Apr; 58(5):739-49. PubMed ID: 21438906
[TBL] [Abstract][Full Text] [Related]
25. CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles.
Beier D; Hau P; Proescholdt M; Lohmeier A; Wischhusen J; Oefner PJ; Aigner L; Brawanski A; Bogdahn U; Beier CP
Cancer Res; 2007 May; 67(9):4010-5. PubMed ID: 17483311
[TBL] [Abstract][Full Text] [Related]
26. Physiologic oxygen concentration enhances the stem-like properties of CD133+ human glioblastoma cells in vitro.
McCord AM; Jamal M; Shankavaram UT; Lang FF; Camphausen K; Tofilon PJ
Mol Cancer Res; 2009 Apr; 7(4):489-97. PubMed ID: 19372578
[TBL] [Abstract][Full Text] [Related]
27. Celecoxib and radioresistant glioblastoma-derived CD133+ cells: improvement in radiotherapeutic effects. Laboratory investigation.
Ma HI; Chiou SH; Hueng DY; Tai LK; Huang PI; Kao CL; Chen YW; Sytwu HK
J Neurosurg; 2011 Mar; 114(3):651-62. PubMed ID: 21054139
[TBL] [Abstract][Full Text] [Related]
28. Overexpression of CD133 enhances chemoresistance to 5-fluorouracil by activating the PI3K/Akt/p70S6K pathway in gastric cancer cells.
Zhu Y; Yu J; Wang S; Lu R; Wu J; Jiang B
Oncol Rep; 2014 Dec; 32(6):2437-44. PubMed ID: 25230779
[TBL] [Abstract][Full Text] [Related]
29. Type 1 collagen as a potential niche component for CD133-positive glioblastoma cells.
Motegi H; Kamoshima Y; Terasaka S; Kobayashi H; Houkin K
Neuropathology; 2014 Aug; 34(4):378-85. PubMed ID: 24673436
[TBL] [Abstract][Full Text] [Related]
30. Chemoresistance of CD133+ cancer stem cells in laryngeal carcinoma.
Yang JP; Liu Y; Zhong W; Yu D; Wen LJ; Jin CS
Chin Med J (Engl); 2011 Apr; 124(7):1055-60. PubMed ID: 21542968
[TBL] [Abstract][Full Text] [Related]
31. Partial biological characterization of cancer stem-like cell line (WJ(2)) of human glioblastoma multiforme.
Wang J; Wang X; Jiang S; Lin P; Zhang J; Wu Y; Xiong Z; Ren JJ; Yang H
Cell Mol Neurobiol; 2008 Nov; 28(7):991-1003. PubMed ID: 18350379
[TBL] [Abstract][Full Text] [Related]
32. Molecular analysis of ex-vivo CD133+ GBM cells revealed a common invasive and angiogenic profile but different proliferative signatures among high grade gliomas.
Garcia JL; Perez-Caro M; Gomez-Moreta JA; Gonzalez F; Ortiz J; Blanco O; Sancho M; Hernandez-Rivas JM; Gonzalez-Sarmiento R; Sanchez-Martin M
BMC Cancer; 2010 Aug; 10():454. PubMed ID: 20735813
[TBL] [Abstract][Full Text] [Related]
33. CD133 expression in osteosarcoma and derivation of CD133⁺ cells.
Li J; Zhong XY; Li ZY; Cai JF; Zou L; Li JM; Yang T; Liu W
Mol Med Rep; 2013 Feb; 7(2):577-84. PubMed ID: 23242469
[TBL] [Abstract][Full Text] [Related]
34. CD133 and DNA-PK regulate MDR1 via the PI3K- or Akt-NF-κB pathway in multidrug-resistant glioblastoma cells in vitro.
Xi G; Hayes E; Lewis R; Ichi S; Mania-Farnell B; Shim K; Takao T; Allender E; Mayanil CS; Tomita T
Oncogene; 2016 Jan; 35(2):241-50. PubMed ID: 25823028
[TBL] [Abstract][Full Text] [Related]
35. The pathological characteristics of glioma stem cell niches.
He H; Li MW; Niu CS
J Clin Neurosci; 2012 Jan; 19(1):121-7. PubMed ID: 22178090
[TBL] [Abstract][Full Text] [Related]
36. Cell surface Nestin is a biomarker for glioma stem cells.
Jin X; Jin X; Jung JE; Beck S; Kim H
Biochem Biophys Res Commun; 2013 Apr; 433(4):496-501. PubMed ID: 23524267
[TBL] [Abstract][Full Text] [Related]
37. Identification of Endothelin-1 and NR4A2 as CD133-regulated genes in colon cancer cells.
Puglisi MA; Barba M; Corbi M; Errico MF; Giorda E; Saulnier N; Boninsegna A; Piscaglia AC; Carsetti R; Cittadini A; Gasbarrini A; Sgambato A
J Pathol; 2011 Oct; 225(2):305-14. PubMed ID: 21826669
[TBL] [Abstract][Full Text] [Related]
38. Prolonged drug selection of breast cancer cells and enrichment of cancer stem cell characteristics.
Calcagno AM; Salcido CD; Gillet JP; Wu CP; Fostel JM; Mumau MD; Gottesman MM; Varticovski L; Ambudkar SV
J Natl Cancer Inst; 2010 Nov; 102(21):1637-52. PubMed ID: 20935265
[TBL] [Abstract][Full Text] [Related]
39. Identification of cancer stem cells from human glioblastomas: growth and differentiation capabilities and CD133/prominin-1 expression.
Gambelli F; Sasdelli F; Manini I; Gambarana C; Oliveri G; Miracco C; Sorrentino V
Cell Biol Int; 2012 Jan; 36(1):29-38. PubMed ID: 21916848
[TBL] [Abstract][Full Text] [Related]
40. CD133+ and nestin+ tumor-initiating cells dominate in N29 and N32 experimental gliomas.
Bexell D; Gunnarsson S; Siesjö P; Bengzon J; Darabi A
Int J Cancer; 2009 Jul; 125(1):15-22. PubMed ID: 19291792
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]